Cellectis (CLLS)

• Market cap: $477M
• 1 day: -1.86%
• 5 days: 10.98%
• 1 month: -5.75%
• 3 months: 41.37%
• 6 months: 218.79%
• Year to date: 162.43%
• 1 year: 214.57%
• 5 years: -84.76%
• 10 years: -84.17%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222